Brief: Oncternal Announces Enrollment Completed And Dosing Initiated For Fifth Dose Cohort Of Phase 1/2 Study Of Onct-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer
30/05/2024 22:25
Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL ANNOUNCES ENROLLMENT COMPLETED AND DOSING
INITIATED
FOR FIFTH DOSE COHORT OF PHASE 1/2 STUDY OF ONCT-534 FOR THE
TREATMENT OF R/R METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
* ONCTERNAL TO PROVIDE ONCT-534 STUDY UPDATE Q3 2024
Source text for Eikon: ID:nGNX4qQXjk
Further company coverage: ONCT.O
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;